Amarin (AMRN) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.
View AMRN analyst ratings or view top-rated stocks.

3 equities research analysts have issued twelve-month price targets for Amarin's stock. Their AMRN share price forecasts range from $1.00 to $3.00. On average, they predict the company's share price to reach $1.81 in the next twelve months. This suggests a possible upside of 95.8% from the stock's current price.
View analysts price targets for AMRN or view top-rated stocks among Wall Street analysts.

Amarin's stock was trading at $1.21 at the start of the year. Since then, AMRN stock has decreased by 23.5% and is now trading at $0.9257.
View the best growth stocks for 2023 here.

Amarin saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 16,500,000 shares, a drop of 9.5% from the August 15th total of 18,240,000 shares. Based on an average daily volume of 2,450,000 shares, the days-to-cover ratio is currently 6.7 days.
View Amarin's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our AMRN earnings forecast.

Amarin Co. plc (NASDAQ:AMRN) issued its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). The biopharmaceutical company had revenue of $80.17 million for the quarter, compared to analyst estimates of $73.40 million. Amarin had a negative net margin of 11.06% and a negative trailing twelve-month return on equity of 6.56%.

43 employees have rated Amarin Chief Executive Officer John Thero on Glassdoor.com. John Thero has an approval rating of 93% among the company's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at Amarin to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Amarin's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ExodusPoint Capital Management LP (0.96%), Woodline Partners LP (0.56%), Price Jennifer C. (0.55%), Gratus Capital LLC (0.46%), Acadian Asset Management LLC (0.29%) and AlphaCentric Advisors LLC (0.14%). Insiders that own company stock include David M Stack, John F Thero, Joseph S Zakrzewski, Michael Wayne Kalb, Olsen Per Wold, Patrick Holt and Steven B Ketchum.
View institutional ownership trends.

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRN stock can currently be purchased for approximately $0.93.

Amarin (NASDAQ:AMRN) has a market capitalization of $373.83 million and generates $369.19 million in revenue each year. The biopharmaceutical company earns $-105,800,000.00 in net income (profit) each year or ($0.09) on an earnings per share basis.

The company employs 365 workers across the globe.

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The official website for the company is www.amarincorp.com. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at investor.relations@amarincorp.com.